Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Human Papillomavirus Protein E6 (E6) Overview 7
Therapeutics Development 8
Human Papillomavirus Protein E6 (E6) - Products under Development by Stage of Development 8
Human Papillomavirus Protein E6 (E6) - Products under Development by Therapy Area 9
Human Papillomavirus Protein E6 (E6) - Products under Development by Indication 10
Human Papillomavirus Protein E6 (E6) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Human Papillomavirus Protein E6 (E6) - Products under Development by Companies 13
Human Papillomavirus Protein E6 (E6) - Products under Development by Universities/Institutes 15
Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development 22
BioNTech AG 22
Cancer Research Technology Limited 23
Etubics Corporation 24
Genexine, Inc. 25
Inovio Pharmaceuticals, Inc. 26
MedImmune, LLC 27
Selecta Biosciences, Inc. 28
Tomegavax, Inc. 29
Transgene SA 30
Human Papillomavirus Protein E6 (E6) - Drug Profiles 31
Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ETBX-041 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
GX-188E - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
human papillomavirus [serotypes 16] vaccine - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
human papillomavirus vaccine - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
INO-3106 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
INO-3112 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
PVX-01 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
SEL-701 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
TA-CIN - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
TG-4001 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
VGX-3100 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Vvax-001 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Human Papillomavirus Protein E6 (E6) - Dormant Projects 51
Human Papillomavirus Protein E6 (E6) - Discontinued Products 52
Human Papillomavirus Protein E6 (E6) - Featured News & Press Releases 53
Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as "Best Therapeutic Vaccine" by World Vaccine Congress 53
Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan 53
Nov 05, 2015: Inovio's INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer 54
Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet 55
Jul 23, 2015: Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial 56
Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress 57
Apr 09, 2015: Inovio Pharmaceuticals HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head & Neck Cancer Patients 58
Dec 23, 2014: Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology 59
Oct 30, 2014: Genexine's HPV Therapeutic Vaccine Achieved High Efficacy in Phase I Cervical Dysplasia Trial 59
Sep 22, 2014: Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 60
Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 60
Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 61
Jun 10, 2014: Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV 62
Jul 01, 2013: Etubics Awarded Grant To Develop HPV Immunotherapy Targeting Head & Neck Cancer 63
Nov 26, 2012: Inovio Pharma's Cytomegalovirus Synthetic Vaccine Generates Strong And Broad T-cell Responses In Preclinical Study 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by BioNTech AG, H2 2016 22
Pipeline by Cancer Research Technology Limited, H2 2016 23
Pipeline by Etubics Corporation, H2 2016 24
Pipeline by Genexine, Inc., H2 2016 25
Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 26
Pipeline by MedImmune, LLC, H2 2016 27
Pipeline by Selecta Biosciences, Inc., H2 2016 28
Pipeline by Tomegavax, Inc., H2 2016 29
Pipeline by Transgene SA, H2 2016 30
Dormant Projects, H2 2016 51
Discontinued Products, H2 2016 52 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy